Description:

ODM derived from http://clinicaltrials.gov/show/NCT00662714

Link:

http://clinicaltrials.gov/show/NCT00662714

Keywords:
Versions (2) ▾
  1. 12/9/13
  2. 4/15/14
Uploaded on:

April 15, 2014

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00662714 Cystic Fibrosis

Details

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
age at least 10 Years
Diagnosed cystic fibrosis
Newly diagnosed Diabetes mellitus in the screening
Exclusion Criteria
Diabetic keto-acidosis (blood glucose > 350 mg/dl and arterial pH < 7.25)
Already treated Diabetes mellitus by oral antidiabetic medication or insulin
Systemic steroid therapy during the last 3 months
Transplantation (status post TX or on the waiting list for TX)
Beginning pulmonary insufficiency, FEV1 < 35% at pulmonary function test in stable condition
Pregnancy, Gestation
Already diagnosed and treated diabetes mellitus
Patients with diabetic keto-acidosis (blood glucose > 350 mg/dl and arterial pH < 7.25) with or without diabetic coma
Severe liver insufficiency (chronic hepatitis B, AST or ALT twice the upper limit of normal, Quick's value < 70% which is a contraindication to use Repaglinide)
Treatment with an indispensable important drug which contraindicates Repaglinide
PEG/ gastric tube/ total parenteral alimentation for more than 4 weeks during the study
CF-patients with type 1 diabetes
Not patient's consent to randomisation and therapeutic trial
Participation on other medical trial
Back to the top of the page